Trastuzumab rezetecan clinical trials
How each study uses trastuzumab rezetecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the trastuzumab rezetecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
103 studies that test it; most in 2026 (42)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 13 |
| 2024 | 10 |
| 2025 | 30 |
| 2026 | 42 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 34 · Other 69
Jiangsu HengRui Medicine Co., Ltd. (20) · Fudan University (14) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (13) · Henan Cancer Hospital (7) · Tianjin Medical University Cancer Institute and Hospital (5) · Sun Yat-sen University (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (4) · Tongji Hospital (3)
Often tested with
Tested in the same studies.
Adebrelimab (18) · Pyrotinib (8) · Famitinib (5) · Tizetatug rezetecan (4) · SHR-1701 (4) · Dalpiciclib (4) · Camrelizumab (4) · Fluzoparib (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Trastuzumab rezetecan is the comparator. A study of two new drugs counts under both.
- 1Pyrotinib · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · next primary completion Dec 2030
- 1Dalpiciclib · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · next primary completion Dec 2030
Reaching primary completion within a year · 18, 3 in phase 3
Studies that test trastuzumab rezetecan, phase 3 first.
- Dec 2026A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxanePhase 3 · Jiangsu HengRui Medicine Co., Ltd.
- May 2027A Study of SHR-A1811 in Subjects With Ovarian CancerPhase 3 · Jiangsu HengRui Medicine Co., Ltd.
- Jun 2027SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing RegimenPhase 3 · Jiangsu HengRui Medicine Co., Ltd.
- Dec 2026A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerPhase 1/2 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Dec 2026A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerPhase 1/2 · Jiangsu HengRui Medicine Co., Ltd.
- Dec 2026A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular TypingPhase 2 · Fudan University
- Dec 2026Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract CancerPhase 2 · Jiangsu HengRui Medicine Co., Ltd.
- Mar 2027Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast CancerPhase 2 · Henan Cancer Hospital
- Mar 2027Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast CancerPhase 2 · First Hospital of China Medical University
- Apr 2027Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract CancerPhase 2 · Peking Union Medical College Hospital
Studies
Open first, then newest update. How each study uses trastuzumab rezetecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 103
- Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJNot yet recruitingPhase 2Fudan UniversityNCT07912957Written as Trastuzumab Rezetecan (SHR-A1811)
- A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung CancerNot yet recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07896005Written as SHR-A1811 Injection
- The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral CrisisRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07203729Written as Trastuzumab Rezetecan
- Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Tongji HospitalNCT07865611Written as Trastuzumab Rezetecan
- SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponseNot yet recruitingPhase 2Fudan UniversityNCT07856303Written as SHR-A1811
- Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07843303Written as Trastuzumab Rezetecan (SHR-A1811)
- Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung CancerNot yet recruitingPhase 2Ming ChenNCT07836543Written as Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab
- Trastuzumab Combined With Retlirafusp Alfa in Treating HER2(Human Epidermal Growth Factor Receptor 2) 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy FailureNot yet recruitingPhase 2Henan Cancer HospitalNCT07817654Written as Trastuzumab Rezetecan+Retlirafusp alfa
- Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07817082Written as SHR- A1811
- A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06840002Written as SHR-A1811
- A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07676162Written as SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab
- A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07679360Written as Trastuzumab Rezetecan for Injection
- Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07802288Written as Trastuzumab Rezetecan + Retlirafusp alfa + CAPOX
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingPhase 2Fudan UniversityNCT06649331Written as SHR-A1811
- A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2Not yet recruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07796763Written as Trastuzumab Rezetecan (SHR-A1811) injection; high dose
- SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast CancerNot yet recruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT07787338Written as SHR-A1811
- A Multicenter, Single-Arm, Prospective Phase II Clinical Study of Trastuzumab Rezetecan Combined With Radiotherapy in Patients With HER2-Mutated Oligoprogressive Advanced Non-Small Cell Lung CancerNot yet recruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07781202Written as Trastuzumab Rezetecan combined with radiotherapy
- A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLCNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07778745Written as Trastuzumab rezetecan
- Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07776171Written as Trastuzumab Rezetecan (SHR-A1811)
- First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) AlterationsNot yet recruitingPhase 2Yongsheng WangNCT07699952Written as Trastuzumab Rezetecan
See all 103 studies that test trastuzumab rezetecan →
Given beside what is tested · 9 — trastuzumab rezetecan is usual care or a partner of the new treatment
- Reverse Triple Negative Immune Resistant Breast CancerRecruitingPhase 2Fudan UniversityNCT05076682Written as SHR-A1811
- Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain MetastasesRecruitingPhase 2Henan Cancer HospitalNCT07100600Written as Trastuzumab Rezetecan
- A Study of SHR-4610 Injection in Patients With Advanced Solid TumorsRecruitingPhase 1/2Shanghai Shengdi Pharmaceutical Co., LtdNCT07231211Written as SHR-A1811 for injection
- Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast CancerRecruitingPhase 2Beijing GoBroad HospitalNCT06433609Written as SHR-A1811
- Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast CancerRecruitingPhase 4Peking University People's HospitalNCT07600164Written as Trastuzumab Rezetecan
- Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast CancerNot yet recruitingPhase 2Xijing HospitalNCT07466303Written as SHR-A1811
- Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver MetastasesNot yet recruitingPhase 2Fudan UniversityNCT07466927Written as SHR-A1811
- Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07102901Written as SHR-A1811 Injection
- A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract CancerRecruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06778031Written as SHR-A1811
As the comparator · 1 — what is tested is compared with trastuzumab rezetecan
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
- Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJNov 3, 2026NCT07912957
- A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung CancerOct 26, 2026NCT07896005
Codes
What other systems call trastuzumab rezetecan · ClinicalTrials.gg INT014248
- UNII (FDA) 1000BJC8CRTRASTUZUMAB REZETECANOne source FDA
- NCI Thesaurus C178312Trastuzumab RezetecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1000BJC8CR | TRASTUZUMAB REZETECAN | One source FDA |
| NCI Thesaurus | C178312 | Trastuzumab Rezetecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.